Wells Fargo slashes price target on Gilead Sciences Inc. [GILD] – find out why.

Gilead Sciences Inc. [NASDAQ: GILD] loss -0.68% on the last trading session, reaching $65.60 price per share at the time. The company report on August 25, 2020 that Diodes Inc. to Participate in the Jefferies Semiconductor, IT Hardware and Communications Infrastructure Conference on September 1.

Diodes Incorporated (Nasdaq: DIOD), today announced Brett Whitmire, Chief Financial Officer, Emily Yang, Vice President of Worldwide Sales and Marketing, and Laura Mehrl, Director of Investor Relations will participate at the Jefferies Semiconductor, IT Hardware and Communications Infrastructure Conference on September 1, 2020, which is being held as a virtual event.

Portfolio managers and analysts who would like to schedule a meeting with management should contact their Jefferies sales representative.

Gilead Sciences Inc. represents 1.26 billion in outstanding shares, while the company has a total market value of $81.69 billion with the latest information. GILD stock price has been found in the range of $65.16 to $65.88.

If compared to the average trading volume of 9.49M shares, GILD reached a trading volume of 7369724 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here is what top equities market gurus are saying about Gilead Sciences Inc. [GILD]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for GILD shares is $77.75 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on GILD stock is a recommendation set at 2.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Wells Fargo have made an estimate for Gilead Sciences Inc. shares, keeping their opinion on the stock as Equal Weight, with their previous recommendation back on July 31, 2020. While these analysts kept the previous recommendation, SunTrust raised their target price from $73 to $74. The new note on the price target was released on July 31, 2020, representing the official price target for Gilead Sciences Inc. stock. Previously, the target price had yet another drop from $89 to $87, while RBC Capital Mkts kept a Outperform rating on GILD stock. On July 31, 2020, analysts decreased their price target for GILD shares from 90 to 85.

The Average True Range (ATR) for Gilead Sciences Inc. is set at 1.40, with the Price to Sales ratio for GILD stock in the period of the last 12 months amounting to 3.68. The Price to Book ratio for the last quarter was 4.57, with the Price to Cash per share for the same quarter was set at 15.19. Price to Free Cash Flow for GILD in the course of the last twelve months was 15.79 with Quick ratio for the last quarter at 2.20.

Trading performance analysis for GILD stock

Gilead Sciences Inc. [GILD] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -0.15. With this latest performance, GILD shares dropped by -11.03% in over the last four-week period, additionally sinking by -9.72% over the last 6 months – not to mention a rise of 3.62% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for GILD stock in for the last two-week period is set at 31.83, with the RSI for the last a single of trading hit 28.21, and the three-weeks RSI is set at 34.65 for Gilead Sciences Inc. [GILD]. The present Moving Average for the last 50 days of trading for this stock 72.80, while it was recorded at 66.06 for the last single week of trading, and 71.53 for the last 200 days.

Gilead Sciences Inc. [GILD]: A deeper dive into fundamental analysis

Operating Margin for any stock indicates how profitable investing would be, and Gilead Sciences Inc. [GILD] shares currently have an operating margin of +22.22 and a Gross Margin at +79.06. Gilead Sciences Inc.’s Net Margin is presently recorded at +24.13.

Return on Total Capital for GILD is now 10.25, given the latest momentum, and Return on Invested Capital for the company is 11.81. Return on Equity for this stock inclined to 24.53, with Return on Assets sitting at 8.60. When it comes to the capital structure of this company, Gilead Sciences Inc. [GILD] has a Total Debt to Total Equity ratio set at 112.40. Additionally, GILD Total Debt to Total Capital is recorded at 52.92, with Total Debt to Total Assets ending up at 41.08. Long-Term Debt to Equity for the company is recorded at 100.87, with the Long-Term Debt to Total Capital now at 47.49.

Reflecting on the efficiency of the workforce at the company, Gilead Sciences Inc. [GILD] managed to generate an average of $456,441 per employee. Receivables Turnover for the company is 6.46 with a Total Asset Turnover recorded at a value of 0.36.Gilead Sciences Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.20 and a Current Ratio set at 2.30.

Gilead Sciences Inc. [GILD]: An earnings per share (EPS) analysis

With the latest financial reports released by the company, Gilead Sciences Inc. posted 1.75/share EPS, while the average EPS was predicted by analysts to be reported at 1.74/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.60%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for GILD. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Gilead Sciences Inc. go to 1.40%.

An analysis of insider ownership at Gilead Sciences Inc. [GILD]

There are presently around $65,252 million, or 81.40% of GILD stock, in the hands of institutional investors. The top three institutional holders of GILD stocks are: CAPITAL RESEARCH GLOBAL INVESTORS with ownership of 125,356,882, which is approximately 30.604% of the company’s market cap and around 0.41% of the total institutional ownership; BLACKROCK INC., holding 115,834,270 shares of the stock with an approximate value of $7.6 billion in GILD stocks shares; and VANGUARD GROUP INC, currently with $6.88 billion in GILD stock with ownership of nearly -2.129% of the company’s market capitalization.

Positions in Gilead Sciences Inc. stocks held by institutional investors increased at the end of July and at the time of the July reporting period, where 787 institutional holders increased their position in Gilead Sciences Inc. [NASDAQ:GILD] by around 87,481,983 shares. Additionally, 846 investors decreased positions by around 99,634,240 shares, while 157 investors held positions by with 807,574,268 shares. The mentioned changes placed institutional holdings at 994,690,491 shares, according to the latest SEC report filing. GILD stock had 152 new institutional investments in for a total of 4,940,660 shares, while 163 institutional investors sold positions of 12,981,378 shares during the same period.

Share on facebook
Share on twitter
Share on linkedin
Share on skype
Share on reddit

Leave a Comment

Your email address will not be published. Required fields are marked *



Download Free eBook For


100% free. stop anytime no spam



Download Free eBook For


100% free. stop anytime no spam